Align Technology, Inc. · ALGN · FY2026 Q1 · Calendar Q2 2026
Align Technology Beats on Record Invisalign Shipments, Reaffirms FY2026 Guidance
Align Technology delivered a strong Q1 2026, with revenue of $1.04 billion (up 6.2% YoY) and EPS of $2.58, beating consensus on both the top and bottom lines. Record Invisalign shipments of 686,000 cases and higher average selling prices drove the upside, with international markets delivering double-digit growth. Gross margins expanded to 70.8% GAAP and 71.8% non-GAAP, supported by operational efficiencies, lower refinement rates, and higher-margin NOAA/Zero-AA configurations. Management reaffirmed full-year FY2026 guidance while acknowledging macro uncertainties including the Middle East conflict. Despite the fundamental beat, shares declined on an abnormal basis post-earnings, suggesting the market had already priced in a strong quarter or was focused on forward risk factors.
Company context
Snapshot as of publicationAlign Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth).…
Earnings scorecard
Reported versus consensusEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | Outperform | Outperform | Maintain | Apr 30, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Apr 24, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Apr 21, 2026 |
| Barclays | Overweight | Equal Weight | Upgrade | Mar 17, 2026 |
| HSBC | Buy | Hold | Upgrade | Feb 9, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 5, 2026 |
| UBS | Neutral | Neutral | Maintain | Feb 5, 2026 |
| Stifel | Buy | Buy | Maintain | Feb 5, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jan 20, 2026 |
| Jefferies | Hold | Buy | Downgrade | Oct 10, 2025 |
| Needham | Hold | Hold | Maintain | May 1, 2025 |
| Leerink Partners | Outperform | Market Perform | Upgrade | Jan 6, 2025 |
| B of A Securities | Underperform | Underperform | Maintain | Dec 13, 2024 |
| Baird | Outperform | Outperform | Maintain | Oct 24, 2024 |
| OTR Global | Mixed | Positive | Downgrade | Jun 4, 2024 |
| Goldman Sachs | Sell | Sell | Maintain | Feb 2, 2024 |
| Stephens & Co. | Overweight | Overweight | Maintain | Jul 28, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | May 4, 2022 |
| Wolfe Research | Outperform | Outperform | Maintain | Jul 29, 2021 |
| BNP Paribas | Outperform | Outperform | Maintain | Jul 8, 2021 |
| SVB Leerink | Outperform | Outperform | Maintain | Apr 29, 2021 |
| Berenberg | Buy | Hold | Upgrade | Apr 22, 2021 |
| Guggenheim | Buy | Buy | Maintain | Apr 18, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 26, 2018 |
| PiperJaffray | Overweight | Overweight | Maintain | May 24, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | May 24, 2018 |
| Deutsche Bank | Hold | Hold | Maintain | Dec 8, 2017 |
| Bank of America | Buy | Neutral | Upgrade | Jul 28, 2017 |
| Roth Capital | Buy | Buy | Maintain | Mar 23, 2016 |
| JMP Securities | Market Perform | Market Outperform | Downgrade | Jan 30, 2015 |
| Barrington Research | Outperform | Market Perform | Upgrade | Apr 7, 2014 |
| Cantor Fitzgerald | Buy | Hold | Upgrade | Oct 18, 2013 |
| Janney Capital | Buy | Buy | Maintain | Jan 29, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $169.64. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $189 | $166.86 | +11.4% | Jul 23, 2026 |
| BMO Capital | Vik Chopra | $209 | $174.68 | +23.2% | Jul 8, 2026 |
| Morgan Stanley | Analyst unavailable | $188 | $190.67 | +10.8% | Apr 24, 2026 |
| Piper Sandler | Jason Bednar | $235 | $191.66 | +38.5% | Apr 21, 2026 |
| Barclays | Glen Santangelo | $200 | $187.68 | +17.9% | Feb 25, 2026 |
| HSBC | Sidharth Sahoo | $200 | $187.6 | +17.9% | Feb 9, 2026 |
| Evercore ISI | Elizabeth Anderson | $200 | $176.27 | +17.9% | Feb 5, 2026 |
| Stifel Nicolaus | Analyst unavailable | $210 | $161.3 | +23.8% | Feb 5, 2026 |
| Wells Fargo | Analyst unavailable | $200 | $173.75 | +17.9% | Feb 5, 2026 |
| Robert W. Baird | Analyst unavailable | $218 | $161.3 | +28.5% | Feb 5, 2026 |
| UBS | Analyst unavailable | $185 | $161.3 | +9.1% | Feb 5, 2026 |
| Piper Sandler | Analyst unavailable | $220 | $161.3 | +29.7% | Feb 5, 2026 |
| Mizuho Securities | Steven Valiquette | $200 | $171.49 | +17.9% | Jan 20, 2026 |
| Barclays | Analyst unavailable | $170 | $157.68 | +0.2% | Dec 8, 2025 |
| Stifel Nicolaus | Jonathan Block | $200 | $141.55 | +17.9% | Oct 30, 2025 |
| Evercore ISI | Analyst unavailable | $170 | $131.91 | +0.2% | Oct 30, 2025 |
| Piper Sandler | Jason Bednar | $200 | $131.91 | +17.9% | Oct 30, 2025 |
| Piper Sandler | Jason Bednar | $190 | $135.98 | +12.0% | Oct 23, 2025 |
| UBS | Analyst unavailable | $155 | $128.43 | -8.6% | Oct 16, 2025 |
| Mizuho Securities | Analyst unavailable | $170 | $125.79 | +0.2% | Oct 13, 2025 |
| Jefferies | Analyst unavailable | $140 | $131.87 | -17.5% | Oct 10, 2025 |
| Evercore ISI | Elizabeth Anderson | $160 | $131.12 | -5.7% | Oct 8, 2025 |
| Mizuho Securities | Analyst unavailable | $210 | $203.57 | +23.8% | Jul 31, 2025 |
| Morgan Stanley | Analyst unavailable | $154 | $142.5 | -9.2% | Jul 31, 2025 |
| Stifel Nicolaus | Jonathan Block | $275 | $207.66 | +62.1% | Oct 24, 2024 |
| Piper Sandler | Jason Bednar | $275 | $221.06 | +62.1% | Oct 24, 2024 |
| Leerink Partners | Michael Cherny | $235 | $207.66 | +38.5% | Oct 24, 2024 |
| Evercore ISI | Elizabeth Anderson | $250 | $207.66 | +47.4% | Oct 24, 2024 |
| Piper Sandler | Jason Bednar | $285 | $216.05 | +68.0% | Oct 17, 2024 |
| Stifel Nicolaus | Jonathan Block | $285 | $229.65 | +68.0% | Oct 11, 2024 |
| Goldman Sachs | Charles Perron-Piche | $225 | $231.04 | +32.6% | Oct 10, 2024 |
| Evercore ISI | Elizabeth Anderson | $270 | $234.85 | +59.2% | Oct 8, 2024 |
| Piper Sandler | Jason Bednar | $315 | $226.05 | +85.7% | Jul 25, 2024 |
| Robert W. Baird | Jeff Johnson | $325 | $251.6 | +91.6% | Jul 22, 2024 |
| Piper Sandler | Jason Bednar | $330 | $242.61 | +94.5% | Jun 21, 2024 |
| Piper Sandler | Jason Bednar | $375 | $305 | +121.0% | Apr 25, 2024 |
| Robert W. Baird | Jeff Johnson | $370 | $313.78 | +118.1% | Apr 25, 2024 |
| Stifel Nicolaus | Jonathan Block | $400 | $300.14 | +135.8% | Apr 18, 2024 |
| Stifel Nicolaus | Jonathan Block | $350 | $314.35 | +106.3% | Mar 15, 2024 |
| Piper Sandler | Jason Bednar | $355 | $320.69 | +109.3% | Mar 13, 2024 |
| Piper Sandler | Jason Bednar | $340 | $257.3 | +100.4% | Sep 9, 2022 |
| Stifel Nicolaus | Jonathan Block | $375 | $252.07 | +121.0% | Jul 26, 2022 |
| UBS | Analyst unavailable | $500 | $361.35 | +194.7% | Apr 26, 2022 |
| Piper Sandler | Analyst unavailable | $600 | $395.05 | +253.7% | Apr 21, 2022 |
| Jefferies | Brandon Couillard | $635 | $446.41 | +274.3% | Apr 3, 2022 |
| Leerink Partners | Richard Newitter | $770 | $621.87 | +353.9% | Jul 28, 2021 |
| Stephens | Chris Cooley | $700 | $627.19 | +312.6% | Jul 9, 2021 |
| BNP Paribas | Julien Ouaddour | $790 | $616.79 | +365.7% | Jul 8, 2021 |
Track every rating change on ALGN the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session closeFollow ALGN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Q1 revenue reached $1.04 billion, up 6.2% YoY, with EPS of $2.58 versus $2.30 estimated (12.2% surprise). Record 686,000 Invisalign cases shipped, with higher ASPs contributing to revenue growth. Gross margin expanded to 70.8% GAAP and 71.8% non-GAAP, while operating margin improved to 13.6% GAAP and 21.5% non-GAAP. International markets (EMEA, APAC, Latin America) delivered double-digit growth, offsetting a modest North America slowdown. New product innovations including Invisalign First, the Pal Expander (IPE), the ART pilot, and Zero-AA/NOAA configurations contributed to margin expansion. The market reaction was negative: shares showed an abnormal decline of 2.3% versus the benchmark's positive move, on volume 1.88x the baseline.
Guidance delta
Management reaffirmed FY2026 guidance with a maintained sentiment. Capex outlook is increasing, with $125-150 million planned for FY2026 manufacturing capacity and technology upgrades. Share repurchases of up to $400 million are authorized for 2026. Management built in prudence for macro risks, particularly the Middle East conflict, but did not adjust the full-year outlook.
Key takeaways
- Q1 revenue of $1.04B and EPS of $2.58 beat consensus estimates on both lines, with EPS surpassing estimates by 12.2%.
- Record 686,000 Invisalign cases shipped, with higher ASPs contributing to revenue growth alongside volume.
- International markets (EMEA, APAC, Latin America) delivered double-digit growth, offsetting a modest North America slowdown.
- Gross margin expanded to 70.8% GAAP driven by higher ASPs, operational efficiencies, and lower refinement rates, with NOAA/Zero-AA configurations adding margin upside.
- Management reaffirmed FY2026 guidance while noting macro risks, especially the Middle East conflict, and committed to $400M in share repurchases and $125-150M in capex.
- A clinical study showed the Invisalign Pal Expander achieved results comparable to traditional Hyrax expanders, and the inaugural ART pilot launched in the U.S. with exocad integration.
Management priorities
- Launch DSP program in APAC in Q2 2026.
- Scale Zero-AA and NOAA configurations across more markets.
- Expand direct 3D printing of attachments and retainers.
- Broaden Invisalign Pay across additional Latin American countries.
- Continue disciplined share repurchases totaling up to $400 million in 2026.
- Invest $125-150 million in FY2026 capex for manufacturing capacity and technology upgrades.
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-31T15:21:00.253458+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T15:21:00.250674+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.